Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

Leukemia

Volumn 26, Issue 5, 2012, Pages 985-990

  Weisberg, E ^a   Azab, A K ^a   Manley, P W ^b   Kung, A L ^c   Christie, A L ^c   Bronson, R ^a   Ghobrial, I M ^a   Griffin, J D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

bone marrow microenvironment; chronic myeloid leukemia; nilotinib; Plerixafor; stem cell mobilization; stromal mediated chemoresistance

Indexed keywords

BCR ABL PROTEIN; CHEMOKINE RECEPTOR CXCR4; NILOTINIB; PLERIXAFOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR VOLUME;

EID: 84860767803     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.360     Document Type: Article

References (42)

1. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 yeras: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
2. Chomel J-C, Bonnet M-L, Sorel N, Bertrand A, Meunier M-C, Fichelson S et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657-3660.
3. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCRABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748-755.
4. Kumagai M, Manabe A, Pui CH, Behm FG, Raimondi SC, Hancock ML et al. Stromasupported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996; 97: 755-760.
5. Ashley DM, Bol SJ, Kannourakis G. Human bone marrow stromal cell contact and soluble factors have different effects on the survival and proliferation of paediatric B-lineage acute lymphoblastic leukaemic blasts. Leuk Res 1994; 18: 337-346.
6. Bradstock K, Bianchi A, Makrynikola V, Filshie R, Gottlieb D. Long-term survival and proliferation of precursor B acute lymphoblastic leukemia cells on human bone marrow stroma. Leukemia 1996; 10: 813-820.
7. Rafii S, Mohle R, Shapiro F, Frey BM, Moore MA. Regulation of hematopoiesis by microvascular endothelium. Leuk Lymphoma 1997; 27: 375-386.
8. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-2396.
9. Lagneaux L, Delforge A, De Bruyn C, Bernier M, Bron D. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leukemia Lymphoma 1999; 35: 445-453.
10. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713-1724.
11. Litwin C, Leong KG, Zapf R, Sutherland H, Naiman SC, Karsan A. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol 2002; 70: 22-30.
12. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
13. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009; 114: 619-629, (IF1/410.5).
14. Azab AK, Azab F, Maiso P, Quang P, Roccaro AM, Sacco A et al. FGFR3 is overexpressed in Waldenström macroglobulinemia and its inhibition by Dovitinib induces apoptosis, and overcomes stroma-induced proliferation. Clin Cancer Res 2011; 17: 4389-4399.
15. Azab F, Azab AK, Maiso P, Calimeri T, Flores LM, Liu Y et al. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's Macroglobulinemia. Clin Cancer Res 2011; e-pub ahead of print 18 October 2011.
16. Azab AK, Quang P, Azab F, Pitsillides C, Tompson B, Chonghaile T et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2011; e-pub ahead of print 16 November 2011.
17. Verfaillie CM. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 1993; 82: 2045-2053.
18. Liesveld JL, Harbol AW, Abboud CN. Stem cell factor and stromal cell co-culture prevent apoptosis in a subculture of the megakaryoblastic cell line, UT-7. Leuk Res 1996; 20: 591-600.
19. Harrison PR, Nibbs RJ, Bartholomew C, O'Prey J, Qiu J, Walker M et al. Molecular mechanisms involved in long-term maintenance of erythroleukaemia cells by stromal cells. Leukemia 1997; 11: 474-477.
20. Breems DA, Blokland EA, Ploemacher RE. Stroma-conditioned media improve expansion of human primitive hematopoietic stem cells and progenitor cells. Leukemia 1997; 11: 42-50.
21. O'Prey J, Leslie N, Itoh K, Ostertag W, Bartholomew C, Harrison PR. Both stroma and stem cell factor maintain long-term growth of ELM erythroleukemia cells, but only stroma prevents erythroid differentiation in response to erythropoietin and interleukin-3. Blood 1998; 91: 1548-1555.
22. Leslie NR, O'Prey J, Bartholomew C, Harrison PR. An activating mutation in the kit receptor abolishes the stroma requirement for growth of ELM erythroleukemia cells, but does not prevent their differentiation in response to erythropoietin. Blood 1998; 92: 4798-4807.
23. Shih CC, Hu MC, Hu J, Medeiros J, Forman SJ. Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. Blood 1999; 94: 623-636.
24. Shaked Y, Cervi D, Neuman M, Chen L, Klement G, Michaud CR et al. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood 2005; 105: 4500-4507.
25. Despars G, O'Neill HC. Splenic endothelial cell lines support development of dendritic cells from bone marrow. Stem Cells 2006; 24: 1496-1504.
26. Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R et al. Stromalmediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008; 7: 1121-1129.
27. Jin L, Tabe Y, Konoplev S, Xu Y, Levsath CE, Lu H et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7: 48-58.
28. Geay JF, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005; 65: 2676-2683.
29. Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma 2009; 50: 1676-1686.
30. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006; 5: 3113-3121.
31. Kalatskaya I, Berchiche Y, Gravel S, Limberg B, Rosenbaum J, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Molecular Pharmocology 2009; 75: 1240-1247.
32. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
33. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM et al. Mechanisms of regulation of CXCR4/SDF1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-2717.
34. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. IL-3 and p210 BCR-ABL activate both unique and overlapping pathways of signal transduction in a factordependent myeloid cell line. Exp Hematol 1993; 21: 1460-1466.
35. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
36. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML et al. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183.
37. Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol 2010; 38: 180-190.
38. Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips II G et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007; 31: 1553-1563.
39. Vianello F, Villanova F, Tisato V, Lymperi S, Ho K-K, Gomes AR et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 2010; 95: 1081-1089.
40. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24: 2100-2109.
41. Agarwal A, Fleischman AG, Petersen CL, Loriaux MM, Woltjer R, Druker BJ et al. Effects of Plerixafor (AMD3100) in Combination with Tyrosine Kinase Inhibition in a Murine Mouse Model of CML. Abstract #3389. 52nd ASH Annual Meeting and Exposition. Dec 4-7, 2010.
42. Burrell K. Role of bone marrow derived cells in response to ionizing radiation in normal brain. Abstract #566. AACR 2011.